MedPath

High Flow Nasal Oxygen Therapy in COVID-19 patients

Not Applicable
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/12/030015
Lead Sponsor
All India Institute of Medical Sciences Jodhpur
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients tested COVID-19 positive by Reverse Transcriptase Polymerase Chain Reaction (rt-PCR) test and admitted in Corona Critical Care wards at AIIMS, Jodhpur till January 31, 2021

- Requiring the use of High FLow Nasal Oxygen Therapy

Exclusion Criteria

- Patients who / whose proxies refuse to consent to use of their data for research

- Patients who were on non-invasive / invasive mechanical ventilation before the use of HFNC (High Flow Nasal Cannula)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The number of patients who did not require intubation and invasive mechanical ventilation by using HFNC as a rescue modality to manage hypoxemia in rt-PCR confirmed Covid-19 patients admitted to the critical care settingTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached
Secondary Outcome Measures
NameTimeMethod
The 28 days all-cause mortality and length of ICU/CCCU stay in these patientsTimepoint: Time of discharge and 28 days post admission;The blood gas parameters (Po2 and PFR) of patients taken on HFNC and their trends over time of useTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached;The duration of HFNC requiredTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached;The validity of using ROX and modified ROX indices as a predictor of intubation and hence failure of HFNCTimepoint: 2hrs, 6hrs, 12hrs and subsequently at 24hr intervals post initiating HFNC use;To compare the data among various demographics and patients with varied comorbiditiesTimepoint: At the time of initiating HFNC and daily at 24hrs intervals after till a positive / negative outcome is reached
© Copyright 2025. All Rights Reserved by MedPath